RxDoctor Payments Data

Dorian Acosta, OD

Optometrist · El Paso, TXNPI 1992274278

Payments from drug & device makers

$1,821in general payments, 2019–2025

Across 83 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$259
  • Oyster Point Pharma, Inc.$208
  • AbbVie$202
  • Biotissue Holdings Inc.$199
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$186
  • Novartis$136
  • plus $631 from 10 others

What the payments were for

  • Food & beverage$1,80399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,821 in reported general payments places this provider in the 70th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$45,971
Medicare patients
234
Services billed
446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner25$50,330
RestasisCyclosporine31$39,806
XiidraLifitegrast12$25,797
VyzultaLatanoprostene Bunod39$19,698
LumiganBimatoprost34$19,358
TyrvayaVarenicline Tartrate20$16,507
Prednisolone Acetate191$9,821
MieboPerfluorohexyloctane/Pf12$9,307
CombiganBrimonidine Tartrate/Timolol28$8,456
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol62$7,019
Alphagan PBrimonidine Tartrate11$4,433
Fluorometholone69$4,175
Travoprost19$2,129
Timolol Maleate26$2,078
Tobramycin-DexamethasoneTobramycin/Dexamethasone23$2,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$202$72,053104 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$101$54,80263 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$125$50,33025 claims
Oyster Point Pharma, Inc.Tyrvaya$208$16,50720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,315 optometrist providers in Texas.

Other optometrist in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →